Zhang Yu, Guan Xin-Yuan, Jiang Peng
Cancer Data Science Lab, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
Department of Clinical Oncology, University of Hong Kong, Hong Kong, Hong Kong.
Front Immunol. 2020 Dec 14;11:594609. doi: 10.3389/fimmu.2020.594609. eCollection 2020.
The success of cancer immunotherapy in solid tumors depends on a sufficient distribution of effector T cells into malignant lesions. However, immune-cold tumors utilize many T-cell exclusion mechanisms to resist immunotherapy. T cells have to go through three steps to fight against tumors: trafficking to the tumor core, surviving and expanding, and maintaining the memory phenotype for long-lasting responses. Cytokines and chemokines play critical roles in modulating the recruitment of T cells and the overall cellular compositions of the tumor microenvironment. Manipulating the cytokine or chemokine environment has brought success in preclinical models and early-stage clinical trials. However, depending on the immune context, the same cytokine or chemokine signals may exhibit either antitumor or protumor activities and induce unwanted side effects. Therefore, a comprehensive understanding of the cytokine and chemokine signals is the premise of overcoming T-cell exclusion for effective and innovative anti-cancer therapies.
癌症免疫疗法在实体瘤中的成功取决于效应T细胞充分分布到恶性病变中。然而,免疫冷肿瘤利用多种T细胞排除机制来抵抗免疫疗法。T细胞对抗肿瘤必须经历三个步骤:迁移到肿瘤核心、存活并扩增,以及维持记忆表型以实现持久反应。细胞因子和趋化因子在调节T细胞募集和肿瘤微环境的整体细胞组成方面发挥着关键作用。在临床前模型和早期临床试验中,操纵细胞因子或趋化因子环境已取得成功。然而,根据免疫背景,相同的细胞因子或趋化因子信号可能表现出抗肿瘤或促肿瘤活性,并引发不良副作用。因此,全面了解细胞因子和趋化因子信号是克服T细胞排除以实现有效和创新抗癌疗法的前提。